A Phase Ib/II Study Investigating the Combination of Everolimus With Trastuzumab and Paclitaxel in Patients With HER2-overexpressing Metastatic Breast Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 29 Apr 2015
At a glance
- Drugs Everolimus (Primary) ; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 10 Jun 2017 Biomarkers information updated
- 06 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Apr 2013 Planned end date changed from 1 Jan 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.